Follow-The-Filings

Security · featured owners

NKTR Nektar Therapeutics

Health Care COM NEW Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 4.2%
  • $22M
  • 1 add 1 exit

NKTR (Nektar Therapeutics) is held in 1 featured 13F book as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (4.2%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 4.2% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel Add 4.2%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
Nathan Fischel - Dafna Capital Management 2026 Q2 4.2% Add +92.7% 318,380 $22M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 4,000 $288K History

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 23 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 1.01,5.02,9.01 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01 Filing Doc
424B5 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01 Filing Doc
424B5 Filing Doc
8-K 7.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Sep 23, 2026 · 5 forms Filing Doc
4 Period Aug 18, 2026 · 2 forms Filing Doc
4 Period Jul 24, 2026 · 2 forms Filing Doc
4 Period Jun 30, 2026 Filing Doc
4 Period Jun 16, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc
4 Period May 19, 2026 · 2 forms Filing Doc
4 Period Feb 18, 2026 · 2 forms Filing Doc
4 Period Jan 20, 2026 Filing Doc

Updated about 2 hours ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $90.12M $98.43M $55.23M
Gross profit * $56.35M $67.74M $55.23M
Gross margin * 62.5% 68.8% 100.0%
Net income -$276.06M -$118.96M -$164.08M
Net margin * -306.3% -120.9% -297.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $330.7M $261.29M $266.27M
Total non-current assets * $67.33M $42.56M $14.14M
Total assets $398.03M $303.85M $280.41M
Total current liabilities $51.27M $61.4M $53.54M
Total non-current liabilities * $215.78M $181.71M $137.04M
Total equity $130.99M $60.74M $89.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$192.61M -$175.71M -$208.51M
Cash from investing $139.56M $142.57M -$1.2M
Cash from financing $0.03M $42.12M $180.57M
Net change in cash -$52.95M $8.98M -$29.14M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders